Additional Relevant Details An ongoing Phase 1 trial that includes a dose-escalation phase, four expansion cohorts of 25 patients each and a Phase 2 expansion cohort of 125 patients with IDH2 mutant-positive AML who are in second or later relapse, refractory to second-line induction or reinduction treatment, or have relapsed after allogeneic transplantation. The primary objectives of the study are to confirm the safety and clinical activity of AG-221 in a select, highly resistant AML population